Catabasis Pharma (CATB) Tops Q4 EPS by 6c

Catabasis Pharma (NASDAQ: CATB) reported Q4 EPS of ($0.55), $0.06 better than the analyst estimate of ($0.61).

“We made excellent progress with our edasalonexent program in 2019 and are in a great place coming into 2020 with the Phase 3 PolarisDMD trial in Duchenne fully enrolled. We also strengthened our financial position. We are preparing for top-line Phase 3 results in the fourth quarter and a subsequent NDA filing in 2021 and have initial commercialization and supply chain preparations underway,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “We are also building for the future with our partnership with Duchenne UK to explore edasalonexent in non-ambulatory Duchenne patients and our ongoing preclinical research to explore the potential for broad benefits of edasalonexent in Duchenne and also in additional neuromuscular diseases.”

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• L3Harris CEO steps down amid conduct review, shares drop
• Royal Unibrew reports higher interim first-half profit as margins improve